LeMaitre (NASDAQ:LMAT) Misses Q2 CY2026 Revenue Estimates, Stock Drops 11.6%
LeMaitre Vascular (NASDAQ:LMAT) reported Q2 CY2026 revenue of $70.38 million, up 9.6% year on year but below Wall Street estimates. Next-quarter revenue guidance was $67.3 million, about 3% under analysts’ expectations. GAAP EPS was $0.74, 8.3% below consensus. The stock fell 11.6% to $93.53 after results.
How this was made
The 30-second read
Why it matters
The key tradable issue is the combination of a Q2 revenue miss and next-quarter revenue guidance coming in below analysts’ estimates, which typically triggers downward revisions and multiple compression for med-tech names with growth narratives.
Market read
LMAT’s guidance shortfall is the dominant catalyst, outweighing the reported YoY sales growth and margin improvement in the near term.
What to watch
The article cites $376M cash and ongoing international warehouse expansions, which could offset near-term revenue softness if inventory and distribution ramp faster than expected.
Background
LeMaitre Vascular reported Q2 CY2026 results, highlighting Artegraft international launch progress and providing next-quarter revenue guidance.
Ticker impact
LeMaitre (LMAT) missed Q2 CY2026 revenue expectations and guided next-quarter revenue to $67.3M, about 3% below estimates, sending shares down 11.6%.
Bearish bias for the next few sessions to weeks, with volatility elevated around further guidance/analyst revisions.
The article provides concrete datapoints: Q2 revenue miss, next-quarter revenue guidance below consensus, and an immediate 11.6% stock drop, which together typically drive estimate cuts and sentiment pressure.
Market effects
Signals potential near-term caution for vascular medical device peers if investors generalize execution risk from guidance softness.
Primarily US small/mid-cap healthcare sentiment, with limited direct regional spillover beyond medical devices.
International launch progress (Artegraft approved in 56 countries) may support longer-term narrative, but the immediate guidance miss is US-driven.
Counterpoint
Despite the miss, sales grew 9.6% YoY and Artegraft is now 21% of sales, suggesting the guidance shortfall could be timing-related rather than a durable demand decline.
Key entities
- companyLeMaitre Vascular
NASDAQ-listed medical device company reporting Q2 CY2026 revenue/EPS and issuing next-quarter revenue guidance.
- personGeorge LeMaitre
Chairman/CEO commenting on Artegraft launch progress, international approvals, and expansion plans.
